Coronary Heart Disease, Hypercholesterolemia, Hyperlipidemia
Conditions
Brief summary
This observational study is being conducted in patients receiving statin treatment as secondary prevention of coronary heart disease under the current standard of care in compliance with European guidelines. The purpose of the study is to evaluate the percentage of these patients that reach target LDL levels. Additionally this study will measure the patient's compliance to treatment as assessed by counting the returned tablets. Both assessments will be made at visits conducted 6-8 weeks after the first visit and 28-32 weeks after the first visit.
Interventions
DRUGStatin
Statin
Sponsors
Merck Sharp & Dohme LLC
Organon and Co
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* willingness to participate in the study * 18 years of age or more * clinically established cardiovascular disease to be considered as patients in secondary prevention * prior therapy with any statin without achieving goal (2.5 mmol/L of LDL cholesterol) at last lipid check performed
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percentage of patients reaching target LDL levels | 6-8 weeks after first visit and 28-32 weeks after first visit |
Secondary
| Measure | Time frame |
|---|---|
| measure patient compliance to treatment as assessed by counting returned tablets | 6-8 weeks after first visit and 28-32 weeks after first visit |
Outcome results
None listed